Symbols / BNGO Stock $1.23 +1.65% Bionano Genomics, Inc.

Healthcare • Medical Instruments & Supplies • United States • NCM
BNGO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Instruments & Supplies
CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.
Exch · Country NCM · United States
Market Cap 13.64M
Enterprise Value 11.05M
Income -26.39M
Sales 28.51M
FCF (ttm) -4.58M
Book/sh 4.14
Cash/sh 1.74
Employees 95
Insider 10d —
IPO Aug 21, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.11
PEG —
P/S 0.48
P/B 0.30
P/C —
EV/EBITDA -0.46
EV/Sales 0.39
Quick Ratio 1.07
Current Ratio 1.98
Debt/Eq 38.03
LT Debt/Eq —
EPS (ttm) -4.85
EPS next Y -1.11
EPS Growth —
Revenue Growth -2.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-23
ROA -27.74%
ROE -66.15%
ROIC —
Gross Margin 46.25%
Oper. Margin -107.36%
Profit Margin -92.59%
Shs Outstand 11.09M
Shs Float 9.96M
Insider Own 7.66%
Instit Own 10.60%
Short Float 10.33%
Short Ratio 1.88
Short Interest 1.15M
52W High 5.50
vs 52W High -77.64%
52W Low 1.06
vs 52W Low 16.04%
Beta 1.60
Impl. Vol. —
Rel Volume 0.22
Avg Volume 330.58K
Volume 73.39K
Target (mean) $5.00
Tgt Median $5.00
Tgt Low $4.00
Tgt High $6.00
# Analysts 2
Recom Strong_buy
Prev Close $1.21
Price $1.23
Change 1.65%
About

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.23
Latest analyst target
3. DCF / Fair value
$-7.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.23
Low
$4.00
High
$6.00
Mean
$5.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-13 main HC Wainwright & Co. Buy → Buy $6
2025-11-24 main HC Wainwright & Co. Buy → Buy $7
2025-08-18 main HC Wainwright & Co. Buy → Buy $11
2025-05-20 up Maxim Group Hold → Buy $8
2025-04-09 init HC Wainwright & Co. — → Buy $10
2025-04-02 main Scotiabank Sector Perform → Sector Perform $4
2024-11-15 down Ladenburg Thalmann Buy → Neutral —
2024-05-16 main BTIG Buy → Buy $2
2024-03-07 main Scotiabank Sector Outperform → Sector Outperform $6
2023-11-13 down Maxim Group Buy → Hold —
2023-08-10 main BTIG Buy → Buy $10
News
RSS: Latest BNGO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-06-03 HOLMLIN R ERIK Chief Executive Officer — 44,000 — —
2024-06-03 OLDAKOWSKI MARK Chief Operating Officer — 16,000 — —
2024-06-03 CHAUBEY ALKA PH.D. Officer — 16,000 — —
2024-06-03 DIXON JONATHAN V General Counsel — 14,500 — —
2024-06-03 KAMA GULSEN Chief Financial Officer — 16,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
28.51
-7.37%
30.78
-14.79%
36.12
+29.90%
27.80
Operating Revenue
28.51
-7.37%
30.78
-14.79%
36.12
+29.90%
27.80
Cost Of Revenue
15.32
-49.59%
30.40
+14.49%
26.55
+21.47%
21.86
Reconciled Cost Of Revenue
15.32
-49.59%
30.40
+14.49%
26.55
+21.47%
21.86
Gross Profit
13.19
+3369.74%
0.38
-96.03%
9.57
+60.91%
5.95
Operating Expense
46.52
-39.31%
76.66
-47.78%
146.79
+6.65%
137.64
Research And Development
11.37
-54.14%
24.80
-54.10%
54.03
+10.16%
49.05
Selling General And Administration
35.15
-32.21%
51.85
-44.10%
92.76
+4.70%
88.60
Total Expenses
61.85
-42.23%
107.05
-38.24%
173.34
+8.68%
159.50
Operating Income
-33.34
+56.29%
-76.28
+44.41%
-137.22
-4.20%
-131.70
Total Operating Income As Reported
-33.34
+67.94%
-103.98
+51.69%
-215.25
-63.44%
-131.70
EBITDA
-16.30
+82.91%
-95.39
+56.94%
-221.52
-83.72%
-120.57
Normalized EBITDA
-16.30
+74.65%
-64.30
+55.19%
-143.50
-19.01%
-120.57
Reconciled Depreciation
9.73
-31.60%
14.23
+2.26%
13.91
+41.38%
9.84
EBIT
-26.03
+76.25%
-109.61
+53.44%
-235.43
-80.53%
-130.41
Total Unusual Items
0.00
+100.00%
-31.08
+60.16%
-78.02
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-31.08
+60.16%
-78.02
0.00
Special Income Charges
0.00
+100.00%
-31.08
+60.16%
-78.02
0.00
Other Special Charges
—
3.38
—
—
Impairment Of Capital Assets
0.00
-100.00%
19.68
-74.53%
77.28
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
8.02
+982.59%
0.74
—
Net Income
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Pretax Income
-26.33
+76.49%
-111.98
+51.82%
-232.43
-77.82%
-130.71
Net Non Operating Interest Income Expense
4.60
+217.60%
-3.91
+77.06%
-17.04
-1509.26%
1.21
Interest Expense Non Operating
0.30
-87.44%
2.37
+179.13%
-3.00
-1106.38%
0.30
Net Interest Income
4.60
+217.60%
-3.91
+77.06%
-17.04
-1509.26%
1.21
Interest Expense
0.30
-87.44%
2.37
+179.13%
-3.00
-1106.38%
0.30
Interest Income Non Operating
4.89
+132.98%
2.10
-36.54%
3.31
+119.71%
1.51
Interest Income
4.89
+132.98%
2.10
-36.54%
3.31
+119.71%
1.51
Other Income Expense
2.41
+107.59%
-31.80
+59.32%
-78.17
-34953.36%
-0.22
Other Non Operating Income Expenses
2.41
+437.15%
-0.72
-383.78%
-0.15
+33.63%
-0.22
Tax Provision
0.07
+103.03%
0.03
-46.77%
0.06
-96.71%
1.88
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-6.53
+60.16%
-16.38
0.00
Net Income Including Noncontrolling Interests
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Net Income From Continuing Operation Net Minority Interest
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Net Income From Continuing And Discontinued Operation
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Net Income Continuous Operations
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Normalized Income
-26.39
+69.82%
-87.46
+48.81%
-170.86
-28.85%
-132.60
Net Income Common Stockholders
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Diluted EPS
-4.85
+91.92%
-60.05
+85.30%
-408.60
-52.63%
-267.71
Basic EPS
-4.85
+91.92%
-60.05
+85.30%
-408.60
-52.63%
-267.71
Basic Average Shares
5.45
+191.89%
1.87
+227.84%
0.57
+14.88%
0.50
Diluted Average Shares
5.45
+191.89%
1.87
+227.84%
0.57
+14.88%
0.50
Diluted NI Availto Com Stockholders
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Total Other Finance Cost
—
3.64
-84.42%
23.35
—
Line Item Trend 2023-12-31
Total Assets
214.40
Current Assets
140.12
Cash Cash Equivalents And Short Term Investments
66.77
Cash And Cash Equivalents
17.95
Other Short Term Investments
48.82
Receivables
9.66
Accounts Receivable
9.32
Gross Accounts Receivable
9.80
Allowance For Doubtful Accounts Receivable
-0.48
Accrued Interest Receivable
0.34
Inventory
22.89
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
4.70
Restricted Cash
35.12
Other Current Assets
0.98
Total Non Current Assets
74.28
Net PPE
32.48
Gross PPE
51.56
Accumulated Depreciation
-19.08
Properties
0.00
Machinery Furniture Equipment
2.98
Other Properties
44.83
Leases
3.75
Goodwill And Other Intangible Assets
33.97
Goodwill
0.00
Other Intangible Assets
33.97
Other Non Current Assets
7.83
Total Liabilities Net Minority Interest
118.25
Current Liabilities
100.03
Payables And Accrued Expenses
13.04
Payables
11.48
Accounts Payable
10.38
Current Accrued Expenses
1.55
Pensionand Other Post Retirement Benefit Plans Current
5.03
Total Tax Payable
1.10
Current Debt And Capital Lease Obligation
2.44
Current Debt
69.80
Other Current Borrowings
69.80
Current Capital Lease Obligation
2.44
Current Deferred Liabilities
0.80
Current Deferred Revenue
0.80
Other Current Liabilities
78.34
Total Non Current Liabilities Net Minority Interest
18.22
Long Term Debt And Capital Lease Obligation
7.17
Long Term Capital Lease Obligation
7.17
Non Current Deferred Liabilities
0.15
Non Current Deferred Revenue
0.15
Other Non Current Liabilities
10.89
Stockholders Equity
96.16
Common Stock Equity
96.16
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.76
Ordinary Shares Number
0.76
Treasury Shares Number
0.00
Additional Paid In Capital
677.34
Retained Earnings
-581.21
Gains Losses Not Affecting Retained Earnings
0.02
Other Equity Adjustments
0.02
Total Equity Gross Minority Interest
96.16
Total Capitalization
96.16
Working Capital
40.09
Invested Capital
96.16
Total Debt
9.61
Net Debt
51.85
Capital Lease Obligations
9.61
Net Tangible Assets
62.19
Tangible Book Value
62.19
Current Provisions
0.39
Interest Payable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-16.34
+76.28%
-68.92
+44.94%
-125.18
-0.29%
-124.82
Cash Flow From Continuing Operating Activities
-16.34
+76.28%
-68.92
+44.94%
-125.18
-0.29%
-124.82
Net Income From Continuing Operations
-26.39
+76.44%
-112.02
+51.82%
-232.49
-75.34%
-132.60
Depreciation Amortization Depletion
9.73
-31.60%
14.23
+2.26%
13.91
+41.38%
9.84
Depreciation
9.73
-31.60%
14.23
+2.26%
13.91
+41.38%
9.84
Depreciation And Amortization
9.73
-31.60%
14.23
+2.26%
13.91
+41.38%
9.84
Other Non Cash Items
0.44
+104.95%
-8.95
-154.51%
16.42
+1968.14%
0.79
Stock Based Compensation
4.53
-53.43%
9.74
-35.85%
15.18
-32.29%
22.42
Provisionand Write Offof Assets
—
—
—
0.65
Asset Impairment Charge
0.00
-100.00%
26.91
-65.17%
77.28
0.00
Deferred Tax
—
—
0.00
-100.00%
1.76
Deferred Income Tax
—
—
0.00
-100.00%
1.76
Operating Gains Losses
0.96
-85.08%
6.45
+1492.10%
0.41
+50.00%
0.27
Gain Loss On Investment Securities
—
0.01
-39.13%
0.02
-65.15%
0.07
Unrealized Gain Loss On Investment Securities
-5.16
+36.46%
-8.12
-1311.83%
-0.57
—
Gain Loss On Sale Of PPE
0.96
-68.54%
3.06
+700.52%
0.38
+87.25%
0.20
Change In Working Capital
0.51
-87.64%
4.16
+128.14%
-14.77
+47.13%
-27.94
Change In Receivables
-0.45
-110.82%
4.14
+280.27%
-2.30
-2.00%
-2.25
Changes In Account Receivables
-0.45
-110.82%
4.14
+280.27%
-2.30
-2.00%
-2.25
Change In Inventory
4.92
+937.48%
-0.59
+85.86%
-4.15
+82.47%
-23.68
Change In Prepaid Assets
-2.06
-230.26%
1.58
+30.50%
1.21
+137.94%
-3.20
Change In Payables And Accrued Expense
-1.95
+65.49%
-5.66
-25.22%
-4.52
-295.12%
2.31
Change In Accrued Expense
-0.58
+74.06%
-2.24
+11.34%
-2.52
-789.07%
0.37
Change In Payable
-1.37
+59.88%
-3.42
-71.43%
-2.00
-202.36%
1.95
Change In Account Payable
-1.37
+59.88%
-3.42
-71.43%
-2.00
-202.36%
1.95
Change In Other Current Assets
0.06
-98.72%
4.68
+193.19%
-5.02
-344.25%
-1.13
Investing Cash Flow
-12.75
-117.26%
73.84
+205.65%
24.16
-70.81%
82.77
Cash Flow From Continuing Investing Activities
-12.75
-117.26%
73.84
+205.65%
24.16
-70.81%
82.77
Net PPE Purchase And Sale
0.00
+100.00%
-0.10
+93.91%
-1.69
+46.72%
-3.17
Purchase Of PPE
0.00
+100.00%
-0.10
+93.91%
-1.69
+47.16%
-3.20
Sale Of PPE
—
—
0.00
-100.00%
0.03
Capital Expenditure
—
-0.10
+93.91%
-1.69
+48.79%
-3.30
Net Investment Purchase And Sale
-12.75
-117.24%
73.94
+187.12%
25.75
-77.93%
116.69
Purchase Of Investment
-241.88
-3.80%
-233.02
-109.43%
-111.26
-32.15%
-84.19
Sale Of Investment
229.13
-25.36%
306.96
+124.03%
137.02
-31.79%
200.89
Net Business Purchase And Sale
—
0.00
-100.00%
0.10
+100.31%
-31.34
Purchase Of Business
—
—
0.00
+100.00%
-31.34
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.10
Purchase Of Intangibles
—
—
0.00
+100.00%
-0.10
Net Other Investing Changes
—
—
—
0.69
Financing Cash Flow
24.04
+275.66%
-13.69
-112.02%
113.81
+394.70%
23.01
Cash Flow From Continuing Financing Activities
24.04
+275.66%
-13.69
-112.02%
113.81
+394.70%
23.01
Net Issuance Payments Of Debt
-4.95
+89.71%
-48.06
-167.73%
70.95
+197191.67%
-0.04
Issuance Of Debt
0.00
-100.00%
18.00
-77.50%
80.00
0.00
Repayment Of Debt
-4.95
+92.51%
-66.06
-630.16%
-9.05
-25030.56%
-0.04
Long Term Debt Issuance
0.00
-100.00%
18.00
-77.50%
80.00
0.00
Long Term Debt Payments
-4.95
+92.51%
-66.06
-630.16%
-9.05
-25030.56%
-0.04
Net Long Term Debt Issuance
-4.95
+89.71%
-48.06
-167.73%
70.95
+197191.67%
-0.04
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
31.10
-30.01%
44.43
-22.99%
57.70
+149.47%
23.13
Proceeds From Stock Option Exercised
0.01
-40.00%
0.01
-88.46%
0.13
-73.63%
0.49
Net Other Financing Charges
-2.12
+78.94%
-10.07
+32.68%
-14.96
-2489.10%
-0.58
Changes In Cash
-5.05
+42.37%
-8.77
-168.54%
12.79
+167.18%
-19.04
Effect Of Exchange Rate Changes
-0.01
-57.14%
-0.01
-110.77%
0.07
+271.05%
-0.04
Beginning Cash Position
9.57
-47.83%
18.35
+234.15%
5.49
-77.65%
24.57
End Cash Position
4.51
-52.90%
9.57
-47.83%
18.35
+234.15%
5.49
Free Cash Flow
-16.34
+76.32%
-69.03
+45.59%
-126.87
+0.97%
-128.12
Interest Paid Supplemental Data
1.67
-84.29%
10.65
+546.42%
1.65
+453.02%
0.30
Amortization Of Securities
-0.98
+25.84%
-1.32
-144.16%
-0.54
-184.48%
0.64
Common Stock Issuance
31.10
-30.01%
44.43
-22.99%
57.70
+149.47%
23.13
Interest Paid CFO
—
—
—
0.00
Issuance Of Capital Stock
31.10
-30.01%
44.43
-22.99%
57.70
+149.47%
23.13
Sale Of Business
—
0.00
-100.00%
0.10
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category